AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
VALENCIA, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ:RCEL, ASX:AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its fourth quarter and full year 2023 financial results after the close of the U.S. financial markets on Thursday, February 22, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, February 23, 2024, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results, business highlights, 2024 revenue guidance, and achievement of cashflow breakeven and GAAP profitability in a specific quarter in 2025.
Related news for (RCEL)
- MoBot alert highlights: NYSE: MSN, NASDAQ: ADAP, NASDAQ: CCCC, NASDAQ: RCEL, NASDAQ: PTNM (09/15/25 12:00 PM)
- MoBot’s Stock Market Highlights – 09/15/25 11:00 AM
- MoBot alert highlights: NASDAQ: HSDT, NASDAQ: RCEL, NYSE: GPUS, NYSE: ATCH, NASDAQ: HYFT (09/15/25 06:00 AM)
- AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific